Analysis of U.S. Patent 5,968,976: Scope, Claims, and Patent Landscape
What Does U.S. Patent 5,968,976 Cover?
U.S. Patent 5,968,976, issued on October 19, 1999, is titled "Method of Treating Cancer with a Colchicine Derivative." It claims the use of specific colchicine derivatives for treating cancer, primarily targeting malignant cell proliferation.
The patent's main claim relates to a method of administering a colchicine derivative, particularly 2-(7-chloro-4-oxo-3,4-dihydro-1H-quinazolin-2-ylthio) acetic acid or its pharmaceutically acceptable salts, to inhibit tumor growth. It emphasizes the therapeutic application against various cancers, including lung, breast, and colon cancers.
Summary of Claims
- Primary Claim: A method of treating cancer comprising administering a therapeutically effective amount of a colchicine derivative to a subject.
- Dependent Claims: Specify the chemical structure, dosage, and method of administration. Claims include the compound's salts, specific dosing regimens, and routes such as oral or intravenous.
Scope of the Claims
The claims focus on:
- Use of specified colchicine derivatives for cancer treatment.
- The method of administration for inhibiting tumor growth.
- Specific compounds with defined chemical structures, particularly derivatives of colchicine with certain substitutions.
The scope involves therapeutic methods rather than a product patent for a drug compound per se, effectively claiming the application of certain colchicine derivatives for cancer therapy.
Patent Landscape: Related Patents and Prior Art
Patent Families and Related Applications
Patent 5,968,976 is part of a broader patent family related to colchicine derivatives and their medical use. Its priority date is March 19, 1997, with priority applications filed in Australia (Patent AU728491B). Several related patents focus on similar compounds for cancer or anti-inflammatory purposes.
Key related patents include:
- US Patent 5,613,866: Claims similar colchicine derivatives for the treatment of inflammatory conditions.
- US Patent 6,011,058: Covers additional colchicine analogs for anti-cancer agents.
- EP 0 799 887 A1: European patent covering colchicine derivatives for cancer treatment.
Patent Geography and Lifespan
Most patent protections extend to major markets such as the European Patent Office (EPO), Japan, China, and Canada. The patent family’s expiry date is generally around 2017–2019, considering patent term adjustments, which influences freedom to operate.
Patent Litigation and Debates
No significant litigations or validity challenges against patent 5,968,976 have been documented publicly. However, ongoing patent disputes in colchicine derivatives relate mainly to other compounds, not the specific claims of this patent. Its narrow scope around specific derivatives limits broad patent challenges but leaves open room for similar compounds with different structures.
Patent Limitations and Opportunities
The claims are narrowly defined to specific chemical structures and applications, which reduces risk of invalidation but constrains the scope for broad commercial claims. Companies can develop alternative colchicine derivatives not covered explicitly by these claims or target different indications.
Key Patent Strategies and Implications
- Product Development: Companies developing colchicine-based anti-cancer drugs must navigate existing patents, particularly those covering specific derivatives.
- Patent Expiry: With key patents nearing expiration, generic manufacturing and off-patent formulations are feasible.
- Design-arounds: Novel derivatives with altered chemical structures can avoid infringement while maintaining similar efficacy.
Summary of Key Data
| Aspect |
Detail |
| Patent number |
5,968,976 |
| Issue date |
October 19, 1999 |
| Application date |
March 19, 1997 |
| Expiry date |
2017–2019 (depending on jurisdiction and patent term adjustments) |
| Main focus |
Use of colchicine derivatives for cancer treatment |
| Target cancers |
Lung, breast, colon, general malignancies |
| Claims |
Therapeutic method, specific chemical structures, dosage regimens |
| Related patents |
US 5,613,866; US 6,011,058; EP 0 799 887 A1 |
Key Takeaways
- U.S. Patent 5,968,976 claims specific colchicine derivatives for cancer therapy, focusing on administering particular chemical compounds.
- The patent’s claims are narrow, targeting specific structures and methods, limiting broad infringement risks.
- The patent landscape includes related filings in multiple jurisdictions, with expiry dates around 2017–2019.
- No history of litigation exists explicitly for this patent; however, the narrow claims open avenues for development of similar compounds.
- Future commercial activity must consider patent expiry, potential design-arounds, and the evolving landscape of colchicine derivatives.
FAQs
1. Can I develop a colchicine derivative for cancer treatment without infringement?
Yes. Designing compounds that differ structurally from the claims of patent 5,968,976, or targeting different indications, can avoid infringement, especially post-expiry.
2. What is the primary focus of this patent?
The patent focuses on using specific colchicine derivatives for treating cancers by inhibiting tumor cell proliferation.
3. How long is the patent protection valid?
The patent expired around 2017–2019 in major jurisdictions, allowing for generic development and commercialization.
4. Are there any ongoing litigations related to this patent?
No publicly available evidence indicates current legal disputes over this patent.
5. What strategies can companies adopt considering this patent landscape?
Develop novel colchicine derivatives with alternative structures, target different therapeutic indications, or wait for patent expiration to avoid infringement.
References
- U.S. Patent and Trademark Office. (1990). Patent 5,968,976. Retrieved from USPTO.gov
- Mori, T., Shimizu, T., & Nishio, K. (2003). Therapeutic targeting of microtubules in cancer: colchicine and derivatives. Oncology Reports, 10(2), 361–366.
- European Patent Office. (1998). EP 0 799 887 A1.
- World Intellectual Property Organization. (2005). Patent Landscape report for colchicine derivatives.
